SCIENTURE HOLDINGS, INC. Interest Expense Nonoperating
SCIENTURE HOLDINGS, INC. (SCNX) reported Interest Expense Nonoperating of $269.79 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $269.79K, a 58.72% decline year-over-year.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $37.02K, a 94.48% decline year-over-year.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $955.50K, a 5.84% decline year-over-year.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $1.80M, a 729.42% increase year-over-year.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for fiscal 2025 was $4.08M, a 205.71% increase from fiscal 2024.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for fiscal 2024 was $1.34M, a 16.83% increase from fiscal 2023.
- SCIENTURE HOLDINGS, INC. interest expense nonoperating for fiscal 2023 was $1.14M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $269.79K 10-Q · filed 2026-08-13 | $306.80K 10-Q · filed 2026-08-13 | $1.26M derived: sum of 3 quarters · filed 2026-08-13 | $3.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $37.02K 10-Q · filed 2026-05-15 | $992.52K derived: sum of 2 quarters · filed 2026-05-15 | $2.80M derived: sum of 3 quarters · filed 2026-05-15 | $3.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $955.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.76M derived: sum of 2 quarters · filed 2026-03-30 | $3.41M derived: sum of 3 quarters · filed 2026-08-13 | $4.08M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.80M 10-Q · filed 2025-11-12 | $2.46M derived: sum of 2 quarters · filed 2026-08-13 | $3.13M 10-Q · filed 2025-11-12 | $4.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $653.49K 10-Q · filed 2026-08-13 | $1.32M 10-Q · filed 2026-08-13 | $2.34M derived: sum of 3 quarters · filed 2026-08-13 | $2.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $670.78K 10-Q · filed 2026-05-15 | $1.69M derived: sum of 2 quarters · filed 2026-05-15 | $1.90M derived: sum of 3 quarters · filed 2026-05-15 | $1.91M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.23M derived: sum of 2 quarters · filed 2026-03-30 | $1.24M derived: sum of 3 quarters · filed 2026-03-30 | $1.34M 10-K · filed 2026-03-30 |
| 2024-09-30 | $217.43K 10-Q · filed 2025-11-12 | $222.38K derived: sum of 2 quarters · filed 2025-11-12 | $320.90K 10-Q · filed 2025-11-12 | $969.22K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.95K 10-Q · filed 2025-08-12 | $103.46K 10-Q · filed 2025-08-12 | $751.78K derived: sum of 3 quarters · filed 2025-08-12 | $1.00M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $98.52K 10-Q · filed 2025-05-12 | $746.83K derived: sum of 2 quarters · filed 2025-05-12 | $998.61K derived: sum of 3 quarters · filed 2025-05-12 | $1.18M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $648.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $900.10K derived: sum of 2 quarters · filed 2025-03-26 | $1.08M derived: sum of 3 quarters · filed 2025-03-26 | $1.14M 10-K · filed 2025-03-26 |
| 2023-09-30 | $251.78K 10-Q · filed 2024-11-06 | $432.51K derived: sum of 2 quarters · filed 2024-11-06 | $494.90K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $180.73K 10-Q · filed 2024-08-09 | $243.13K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |